ULK1 as a therapeutic target in kidney diseases: Current perspective

Please use this identifier to cite or link to this item: http://dspace.bits-pilani.ac.in:8080/jspui/handle/123456789/18384

Full metadata record

DC Field	Value	Language
dc.contributor.author	Gaikwad, Anil Bhanudas	-
dc.date.accessioned	2025-03-17T04:45:44Z	-
dc.date.available	2025-03-17T04:45:44Z	-
dc.date.issued	2024-11	-
dc.identifier.uri	https://www.tandfonline.com/doi/full/10.1080/14728222.2024.2421762	-
dc.identifier.uri	http://dspace.bits-pilani.ac.in:8080/jspui/handle/123456789/18384	-
dc.description.abstract	Globally, ~850 million people are affected by different kidney diseases. The pathogenesis of kidney diseases is intricate, where autophagy is crucial for maintaining kidney homeostasis. Iteliminates damaged organelles, thus reducing renal lesions and allowing tissue regeneration. Therefore, targeting various autophagy proteins, e.g. Unc–51–like autophagy-activating kinase 1 (ULK1), is emerging as potential therapeutic strategy against kidney disease.	en_US
dc.language.iso	en	en_US
dc.publisher	Taylor & Francis	en_US
dc.subject	Pharmacy	en_US
dc.subject	Autophagy	en_US
dc.subject	Kidney diseases	en_US
dc.subject	ULK1	en_US
dc.subject	Therapeutic target	en_US
dc.subject	Kidney homeostasis	en_US
dc.title	ULK1 as a therapeutic target in kidney diseases: Current perspective	en_US
dc.type	Article	en_US
Appears in Collections:	Department of Pharmacy

Files in This Item:

There are no files associated with this item.